GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » EBIT

Hisamitsu Pharmaceutical Co (TSE:4530) EBIT : 円19,204 Mil (TTM As of Nov. 2023)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co EBIT?

Hisamitsu Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2023 was 円5,026 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2023 was 円19,204 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hisamitsu Pharmaceutical Co's annualized ROC % for the quarter that ended in Nov. 2023 was 6.05%. Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2023 was 26.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hisamitsu Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2023 was 11.69%.


Hisamitsu Pharmaceutical Co EBIT Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co EBIT Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,174.00 12,207.00 12,976.00 16,128.00 19,204.00

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,087.00 5,712.00 5,933.00 5,026.00 2,533.00

Competitive Comparison of Hisamitsu Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's EV-to-EBIT falls into.



Hisamitsu Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円19,204 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co  (TSE:4530) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hisamitsu Pharmaceutical Co's annualized ROC % for the quarter that ended in Nov. 2023 is calculated as:

ROC % (Q: Nov. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2023 ) + Invested Capital (Q: Nov. 2023 ))/ count )
=15496 * ( 1 - 24.14% )/( (189913 + 198630)/ 2 )
=11755.2656/194271.5
=6.05 %

where

Note: The Operating Income data used here is four times the quarterly (Nov. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Nov. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2023  Q: Nov. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=20104/( ( (50968 + max(20357, 0)) + (51025 + max(26994, 0)) )/ 2 )
=20104/( ( 71325 + 78019 )/ 2 )
=20104/74672
=26.92 %

where Working Capital is:

Working Capital(Q: Aug. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(41967 + 20547 + 10966) - (12958 + 0 + 40165)
=20357

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(42412 + 21606 + 12251) - (12367 + 0 + 36908)
=26994

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hisamitsu Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Nov. 2023 )
=19204/164299.861
=11.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines